Drug intelligence / Profile preview

EnceVir Neo

Development stage: Unknown
Lead developer: SPA Microgen
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

EnceVir Neo is an inactivated vaccine developed by NPO Microgen (a subsidiary of Nacimbio) for the specific prevention of tick-borne encephalitis (TBE) in children and adolescents aged 3 to 17 years. The vaccine consists of a sterile purified concentrated suspension of formalin-inactivated tick-borne encephalitis virus (strain 205), produced in chick embryo cell cultures and adsorbed onto aluminum hydroxide. It works by inducing active immunity against the TBE virus, providing protection for individuals residing in or traveling to endemic regions. The formulation is administered via intramuscular injection and is free of antibiotics and preservatives.

Brand names: EnceVir Neo
Other names: Children's tick-borne encephalitis vaccineEnceVir Neo for childrentick-borne encephalitis vaccine (children)

Beyond the preview

Go deeper on EnceVir Neo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnceVir Neo.

Explore the full profile